GlobeNewsWire
21 Sept 2026, 11:30 UTC · 1h ago
Verdict
Headline takes no side. We score CYBN +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Helus Pharma released 12-month efficacy results from its Phase 1/2a study of HLP003 for major depressive disorder.
Newannounced today, Sept 21, 2026
So whatLong-term durability data is a key requirement for FDA approval in MDD, directly affecting the probability of success for the ongoing Phase 3 PARADIGM trial.
More positive than 92% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The company presented a trial-in-progress overview of the ongoing Phase 3 PARADIGM clinical program for HLP003.
Newannounced today, Sept 21, 2026
So whatConfirmation of program progression suggests the company is on track for its next major clinical milestone, likely in late 2026 or 2027.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
As the parent company of Helus Pharma, Cybin benefits from the positive clinical updates and FDA Breakthrough Therapy Designation for HLP003.
More positive than 70% of ticker scores this week
The company is presenting positive clinical data for HLP003 and advancing its Phase 3 clinical program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
—
No price for CYBN right now — the quote feed didn't answer.
CYBN chart →
